CY2017041I2 - Συνθεσεις για επηρεασμο απωλειας βαρους που περιλαμβανουν ανταγωνιστη οπιοειδους και μπουπροπιονη - Google Patents

Συνθεσεις για επηρεασμο απωλειας βαρους που περιλαμβανουν ανταγωνιστη οπιοειδους και μπουπροπιονη

Info

Publication number
CY2017041I2
CY2017041I2 CY2017041C CY2017041C CY2017041I2 CY 2017041 I2 CY2017041 I2 CY 2017041I2 CY 2017041 C CY2017041 C CY 2017041C CY 2017041 C CY2017041 C CY 2017041C CY 2017041 I2 CY2017041 I2 CY 2017041I2
Authority
CY
Cyprus
Prior art keywords
bupropion
compositions
weight loss
opioid antagonist
affecting weight
Prior art date
Application number
CY2017041C
Other languages
English (en)
Other versions
CY2017041I1 (el
Original Assignee
Orexigen Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP04760321A external-priority patent/EP1617832B1/en
Application filed by Orexigen Therapeutics, Inc. filed Critical Orexigen Therapeutics, Inc.
Publication of CY2017041I2 publication Critical patent/CY2017041I2/el
Publication of CY2017041I1 publication Critical patent/CY2017041I1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CY2017041C 2003-04-29 2017-12-11 Συνθεσεις για επηρεασμο απωλειας βαρους που περιλαμβανουν ανταγωνιστη οπιοειδους και μπουπροπιονη CY2017041I1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US46683803P 2003-04-29 2003-04-29
EP04760321A EP1617832B1 (en) 2003-04-29 2004-04-21 Compositions for affecting weight loss
EP07116330A EP1870096A3 (en) 2003-04-29 2004-04-21 Compositions for affecting weight loss

Publications (2)

Publication Number Publication Date
CY2017041I2 true CY2017041I2 (el) 2018-09-05
CY2017041I1 CY2017041I1 (el) 2018-09-05

Family

ID=38719840

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20171100932T CY1119418T1 (el) 2003-04-29 2017-09-05 Συνθεσεις για επηρεασμο απωλειας βαρους που περιλαμβανουν ανταγωνιστη οπιοειδους και μπουπροπιονη
CY2017041C CY2017041I1 (el) 2003-04-29 2017-12-11 Συνθεσεις για επηρεασμο απωλειας βαρους που περιλαμβανουν ανταγωνιστη οπιοειδους και μπουπροπιονη

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CY20171100932T CY1119418T1 (el) 2003-04-29 2017-09-05 Συνθεσεις για επηρεασμο απωλειας βαρους που περιλαμβανουν ανταγωνιστη οπιοειδους και μπουπροπιονη

Country Status (6)

Country Link
EP (1) EP1870096A3 (el)
BE (1) BE2017C064I2 (el)
CY (2) CY1119418T1 (el)
FR (1) FR17C1058I2 (el)
LU (1) LUC00054I2 (el)
NL (1) NL300918I2 (el)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012111011A2 (en) 2011-02-16 2012-08-23 Nir Barak Low dosage combinations of fluoxetine and reboxetine for treating obesity
EP2950799B1 (en) 2013-01-30 2019-12-04 Pharmorx Therapeutics, Inc. Treatments for depression and other diseases with a low dose agent

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4217353A (en) * 1978-05-19 1980-08-12 E. I. Du Pont De Nemours And Company Method for inducing anorexia
AU3419995A (en) * 1994-09-19 1996-04-09 Du Pont Merck Pharmaceutical Company, The Combination of an opioid antagonist and a selective serotonin reuptake inhibitor for treatment of alcoholism and alcohol dependence
WO1997041873A1 (en) * 1996-05-07 1997-11-13 Ergo Research Corporation Method and composition for the treatment of lipid and glucose metabolism disorders
EP1051167A1 (en) * 1998-01-29 2000-11-15 Sepracor, Inc. Pharmaceutical uses of optically pure (-) -bupropion
US6071918A (en) * 1999-07-21 2000-06-06 Dupont Pharmaceuticals Company Combination of an opioid antagonist and a selective serotonin reuptake inhibitor for treatment of alcoholism and alcohol dependence
US6403657B1 (en) * 1999-10-04 2002-06-11 Martin C. Hinz Comprehensive pharmacologic therapy for treatment of obesity
WO2001052851A1 (en) * 2000-01-22 2001-07-26 Albert Shulman Methods for the treatment of substance abuse
US6770620B2 (en) * 2000-09-18 2004-08-03 Sanos Bioscience A/S Use of GLP for the treatment, prevention, diagnosis, and prognosis of bone-related and nutrition-related disorders
US20030087896A1 (en) * 2001-08-09 2003-05-08 Hillel Glover Treatment of refractory depression with an opiate antagonist and an antidepressant
US20040102440A1 (en) * 2002-07-01 2004-05-27 Wong Erik Ho Fong Method of promoting smoking cessation
EP2074997A1 (en) * 2002-05-17 2009-07-01 Tioga Pharmaceuticals, Inc. Use of Asimadoline for the treatment of digestive disorders
US6972291B2 (en) * 2002-07-02 2005-12-06 Bernstein Richard K Method for reducing food intake

Also Published As

Publication number Publication date
EP1870096A3 (en) 2011-04-20
NL300918I1 (nl) 2017-12-14
CY1119418T1 (el) 2018-03-07
EP1870096A2 (en) 2007-12-26
FR17C1058I1 (el) 2018-01-12
FR17C1058I2 (fr) 2019-01-11
BE2017C064I2 (el) 2023-08-09
LUC00054I1 (el) 2017-12-13
LUC00054I2 (el) 2018-02-21
CY2017041I1 (el) 2018-09-05
NL300918I2 (nl) 2018-01-09

Similar Documents

Publication Publication Date Title
CY2011013I2 (el) Στερεες φαρμακευτικες συνθεσεις οι οποιες περιλαμβανουν εναν αγωνιστη υποδοχεα s1p και μια αλκοολη σακχαρων
LTC1694363I2 (lt) Monodispersinės pegiliuoto naloksolio kompozicijos
IL171285A (en) Pharmaceuticals containing interleukin-6 antagonist and their uses
DE60331751D1 (de) N-substituierte 2-oxodihydropyridinderivate als npy antagonisten
IL174909A (en) Pharmaceutical compositions containing an interleukin-6 antagonist
DK3536344T3 (da) Superfin formoterolformulering
IL176122A0 (en) Pharmaceutical compositions containing an interleukin-6 antagonist
DK1682142T3 (da) M3-muscarin-acetylcholin-receptor-antagonister
FR2862654B1 (fr) Composition amylacee filmogene
ATE354631T1 (de) Nuancierungsmittel
HK1083096A1 (en) Casr antagonist casr
DE602004007143D1 (de) Härtbare perfluorelastomerzusammensetzungen
NO20051956D0 (no) Salmeterol superfin formulering
DK1425019T3 (da) Farmaceutisk sammensætning omfattende et androgen
IL178461A0 (en) Substituted 4-alkyl -and 4-alkanoyl-piperidine derivatives and their use as neurokinin antagonists
ATE417648T1 (de) Stifte zusammensetzungen
ATE403651T1 (de) 3-fluoro-piperidine als nmda/nr2b antagonisten
ATE432077T1 (de) 5-arylpyrimidine als anti-krebs-mittel
DE602004016671D1 (de) Testvorrichtung
CY2017041I1 (el) Συνθεσεις για επηρεασμο απωλειας βαρους που περιλαμβανουν ανταγωνιστη οπιοειδους και μπουπροπιονη
NO20060375L (no) Famasoytisk preparat
NO20054040D0 (no) Utslagsmatte for golf
DE602004016159D1 (de) Testeinrichtung
DE602004010287D1 (de) Testvorrichtung
AU2002307802A8 (en) Antagonists of megalin or cubilin for use in preventing organ damage induced by therapeutic agents